Who We Are
B2S Life Sciences® is a biotherapeutic enablement company advancing improved analytical methods and outcomes for companies involved in the development of biotherapeutic drugs and diagnostics. We aren’t your typical CRO.
Our mission is to leverage our extensive expertise in bioanalytical methods, development and statistical analysis to help ensure technical success, create value and make a positive impact on discovery and development projects and regulatory submissions for our clients’ therapeutic products and devices.
We provide superior custom reagent products and services that are tailored to our clients’ needs and manage these products and services for clients throughout the drug development process with Pre-Analytical and Post-Analytical services.
Our combination of expertise, products, and services thereby uniquely qualifies us to better the development process for biotherapeutic drugs, CROs, pharma, biotech and diagnostics.
Incorporated in 2002 as Bowsher Brunelle Smith LLC (d/b/a B2S Consulting®), we were founded as an Indianapolis-based firm offering a range of consulting services to support research and development of biotherapeutics and conventional pharmaceuticals.
Leveraging decades of combined experience in drug development and applied statistics, Dr. Bowsher and his business partners offered cutting-edge and in-depth support for nonclinical and clinical drug development.
In January 2017, our core competencies were consolidated under the network of B2S Life Sciences®, a service-driven Biotherapeutic Enablement Company offering premier laboratory analysis and life cycle management of custom reagents.
Today, B2S Life Sciences® serves pharma and biotechnology clients by offering a wide range of Pre-Analytical (generation of custom reagents) and Post-Analytical (data analytics and statistics, pharmacokinetic data analysis and clinical immunogenicity) services.